01 Apr, EOD - Indian

Nifty Next 50 61912.75 (2.59)

Nifty Pharma 22011.6 (-0.99)

Nifty Midcap 100 53819.15 (2.22)

Nifty Smallcap 100 15709.8 (3.33)

Nifty 50 22679.4 (1.56)

Nifty IT 29669.05 (2.09)

SENSEX 73134.32 (1.65)

Nifty Bank 51448.65 (2.33)

01 Apr, EOD - Global

NIKKEI 225 53739.68 (5.24)

HANG SENG 25294.03 (2.04)

S&P 6626.87 (1.18)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(01 Apr 2026, 13:15)

Marksans Pharma gains on securing USFDA approval for Benzonatate Capsules

Marksans Pharma soared 7.92% to Rs 169.60 after the company has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg and 200 mg.


The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, marketed by Pfizer Inc.

Benzonatate is a non-narcotic antitussive that works by numbing stretch receptors in the respiratory tract, thereby suppressing the cough reflex. It is commonly used for the symptomatic relief of persistent cough associated with conditions such as bronchitis, pneumonia, and other respiratory infections.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit increased 8.26% year-on-year to Rs 113.20 crore, despite a 10.64% jump in revenue from operations to Rs 754.42 crore in Q3 FY26 compared with Q3 FY25.

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +